Clinical Trial: Efficacy of Zelpultide Alfa in Preterm Neonates At High Risk of Developing Bronchopulmonary Dysplasia (BPD)

U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT06897839) titled 'Efficacy of Zelpultide Alfa in Preterm Neonates At High Risk of Developing Bronchopulmonary Dysplasia (BPD)' on Feb. 20.

Brief Summary: The goal of this Randomized, Double-Blind, Parallel-Group, Phase 3 Multicenter Study is to determine if an investigational drug, Zelpultide Alfa, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD) in extremely premature babies.

The main objective is to compare the efficacy of zelpultide alfa added to standard of care (SOC) versus SOC plus placebo (air-sham) in terms of incidence of grade 2 and grade 3 bronchopulmonary dysplasia (BPD) and death in neonates at high risk for developing BPD...